Barrington Research Maintains Outperform on Cross Country Healthcare, Lowers Price Target to $19
Barrington Research Maintains Outperform on Cross Country Healthcare, Lowers Price Target to $19
Barrington Research維持對cross country healthcare的表現評級，將目標價下調至$19
Barrington Research analyst Kevin Steinke maintains Cross Country Healthcare (NASDAQ:CCRN) with a Outperform and lowers the price target from $21 to $19.
Barrington Research分析師Kevin Steinke維持Cross Country Healthcare（納斯達克：CCRN）爲超越市場表現，並將目標價從21美元降至19美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。